Effexor Clinical Trials

Browse 6 Effexor Medical Studies Across 24 Cities

1 Phase 3 Trial · 26 Effexor Clinics

Reviewed by Michael Gill, B. Sc.
6 Effexor Clinical Trials Near Me
Top Cities for Effexor Clinical Trials
Image of La Jolla in California.
La Jolla
2Active Trials
Altman Clinical and Translational Research Institute BuildingTop Active Site
Image of Stanford in California.
2Active Trials
Stanford UniversityTop Active Site
Effexor Clinical Trials by Phase of Trial
Phase 2 Effexor Clinical Trials
1Active Effexor Clinical Trials
1Number of Unique Treatments
2Number of Active Locations
Most Recent Effexor Clinical Trials

What Are Effexor Clinical Trials?

Effexor (venlafaxine), is a chemical compound developed by the Pfizer pharmaceutical company. It is in the family of serotonin - norepinephrine reuptake inhibitors. Prior to its approval by the FDA in 1993, researchers were studying how the drug worked on everything from fibromyalgia to anxiety, depression, even agoraphobia. Researchers became hopeful about its clinical trial success with improving the mood, energy, and overall participation of non-placebo participants. It has been shown to work better than many other anti-depressant compounds during clinical studies.

Why Is Effexor Being Studied In Clinical Trials?

Researchers are always conducting clinical studies of Effexor to ensure its safety, efficacy, interactions with other medications, as well as to find new uses for it and ways to improve it. For instance, Effexor was only available in immediate release form. Due to a clinical study conducted in 2008, it was found that it was more effective in extended release form. Pfizer developed an extended release in 2010. Clinical studies were also responsible for finding that older adults responded better to Effexor than other medications. Research studies also found that combining Effexor with suboxene can improve, difficult to treat, major depressive disorder. The effect on dosage levels has also been studied to try and reduce the frequency of side effects.

How Does Effexor Treatment Work?

Effexor works by increasing the levels of natural mood enhancing chemicals in the brain. Effexor is a serotonin and norepinephrine reuptake inhibitor (SNRI). These chemicals, when balanced, will improve your mood, energy, and interest in daily life. A physician will determine which of the 3 dosage amounts is right for an individual. When taking Effexor, patients must communicate with their doctor about any side effects they may be experiencing. These side effects could include loss of appetite, dizziness, sweating, insomnia, or suicidal thoughts.

What Are Some Breakthrough Clinical Trials Involving The Use Of Effexor?

2012: A study conducted in the Netherlands evaluated the relationship between violence, specifically homicide and suicide rates, and the use of Effexor.

2018: A study done by the Washington University School of Medicine found that the use of Effexor along with the drug Suboxene ( used for opioid withdrawal) can increase the success rate when treating patients with treatment resistant depression.

Who Are The Key Opinion Leaders On Effexor Clinical Trial Research?

Andrew Leuchter,M.D. is a professor of Psychiatry at the Semel Institute for Neuroscience and Human Behavior at UCLA. He has written over 200 articles about the treatment of depression, including one of the first on a study he conducted on the effectiveness of Effexor to treat major depressive disorder.

Eric Lenze is a Wallace Renard professor of Psychiatry at Washington University in St. Louis, MO. He has been researching treatment methods for anxiety, depression, and brain health in older adults for over 20 years. He has conducted studies and published his findings on the different uses of Effexor with older adults who have difficult to treat psychiatric issues.

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 18th, 2021

Last Reviewed: September 8th, 2023

References1 Williams LM, Korgaonkar MS, Song YC, Paton R, Eagles S, Goldstein-Piekarski A, Grieve SM, Harris AW, Usherwood T, Etkin A. Amygdala Reactivity to Emotional Faces in the Prediction of General and Medication-Specific Responses to Antidepressant Treatment in the Randomized iSPOT-D Trial. Neuropsychopharmacology. 2015 Sep;40(10):2398-408. doi: 10.1038/npp.2015.89. Epub 2015 Mar 31. https://pubmed.ncbi.nlm.nih.gov/258244242 Williams LM, Rush AJ, Koslow SH, Wisniewski SR, Cooper NJ, Nemeroff CB, Schatzberg AF, Gordon E. International Study to Predict Optimized Treatment for Depression (iSPOT-D), a randomized clinical trial: rationale and protocol. Trials. 2011 Jan 5;12:4. doi: 10.1186/1745-6215-12-4. https://pubmed.ncbi.nlm.nih.gov/212084173 Korgaonkar MS, Fornito A, Williams LM, Grieve SM. Abnormal structural networks characterize major depressive disorder: a connectome analysis. Biol Psychiatry. 2014 Oct 1;76(7):567-74. doi: 10.1016/j.biopsych.2014.02.018. Epub 2014 Mar 6. https://pubmed.ncbi.nlm.nih.gov/246901114 Rajpurkar P, Yang J, Dass N, Vale V, Keller AS, Irvin J, Taylor Z, Basu S, Ng A, Williams LM. Evaluation of a Machine Learning Model Based on Pretreatment Symptoms and Electroencephalographic Features to Predict Outcomes of Antidepressant Treatment in Adults With Depression: A Prespecified Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2020 Jun 1;3(6):e206653. doi: 10.1001/jamanetworkopen.2020.6653. Erratum in: JAMA Netw Open. 2020 Jul 1;3(7):e2016001. https://pubmed.ncbi.nlm.nih.gov/325683995 Bredemeier K, Larsen S, Shivakumar G, Grubbs K, McLean C, Tress C, Rosenfield D, DeRubeis R, Xu C, Foa E, Morland L, Pai A, Tsao C, Crawford J, Weitz E, Mayinja L, Feler B, Wachsman T, Lupo M, Hooper V, Cook R, Thase M. A comparison of prolonged exposure therapy, pharmacotherapy, and their combination for PTSD: What works best and for whom; study protocol for a randomized trial. Contemp Clin Trials. 2022 Jul 13;119:106850. doi: 10.1016/j.cct.2022.106850. [Epub ahead of print] https://pubmed.ncbi.nlm.nih.gov/358421086 Braund TA, Palmer DM, Williams LM, Harris AWF. Dimensions of anxiety in Major depressive disorder and their use in predicting antidepressant treatment outcome: an iSPOT-D report. Psychol Med. 2020 Apr;50(6):1032-1042. doi: 10.1017/S0033291719000941. Epub 2019 Apr 26. https://pubmed.ncbi.nlm.nih.gov/310233987 Kircanski K, Williams LM, Gotlib IH. Heart rate variability as a biomarker of anxious depression response to antidepressant medication. Depress Anxiety. 2019 Jan;36(1):63-71. doi: 10.1002/da.22843. Epub 2018 Oct 12. https://pubmed.ncbi.nlm.nih.gov/303117428 Goldstein-Piekarski AN, Korgaonkar MS, Green E, Suppes T, Schatzberg AF, Hastie T, Nemeroff CB, Williams LM. Human amygdala engagement moderated by early life stress exposure is a biobehavioral target for predicting recovery on antidepressants. Proc Natl Acad Sci U S A. 2016 Oct 18;113(42):11955-11960. Epub 2016 Oct 10. https://pubmed.ncbi.nlm.nih.gov/277910549 Korgaonkar MS, Williams LM, Song YJ, Usherwood T, Grieve SM. Diffusion tensor imaging predictors of treatment outcomes in major depressive disorder. Br J Psychiatry. 2014 Oct;205(4):321-8. doi: 10.1192/bjp.bp.113.140376. Epub 2014 Jun 26. https://pubmed.ncbi.nlm.nih.gov/2497077310 Keller AS, Ball TM, Williams LM. Deep phenotyping of attention impairments and the 'Inattention Biotype' in Major Depressive Disorder. Psychol Med. 2020 Oct;50(13):2203-2212. doi: 10.1017/S0033291719002290. Epub 2019 Sep 3. https://pubmed.ncbi.nlm.nih.gov/31477195